(Hong Kong, 10 July, 2020) Ocumension Therapeutics (“Ocumension” or the “Company”, together with its subsidiaries, the “Group”, stock code: 1477), a China-based ophthalmic pharmaceutical platform company, was successfully listed and commenced dealings on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”) today, with a board lot of 500 Shares.

Shares of Ocumension Therapeutics were actively traded on the first trading day, opened 193.3% higher, and the performance of the stock market was very satisfactory. Its share price closed at HK$37 with an intra-day high of HK$43 per share. A total of approximately 59.1 million shares were traded, with an aggregate turnover of approximately HK$2.395 billion.

Mr. Ye LIU, the CEO and Executive Director of Ocumension Therapeutics said, “Getting listed on the Hong Kong Stock Exchange is an important milestone in the Company’s development. We are very grateful for the support and attention from all our investors. Listing in Hong Kong not only enables the Company to enter into the international capital markets but also provides funds for the long-term development of the Company to grasp development opportunities in the industry. We are very honored to receive enthusiastic support from international investors during the global offering. With our leading market position and competitive advantages, Ocumension Therapeutics will be able to capture these opportunities and explore new business opportunities and markets. Looking into the future, we plans to advance clinical development and commercialization of key drug candidates and strategically seek global out-licensing opportunities to maximize the value to our shareholders.”